IJSRP, Volume 9, Issue 6, June 2019 Edition [ISSN 2250-3153]
Rini Syahrani Harahap, Delyuzar, Soekimin
Background : Most patients with NSCLC are diagnosed in advanced stage. Several investigators evaluated the possibility to modulate the immune system for treating lung cancer. PD-L1 expression on tumour cells leads to the inhibition of immune responses against cancer. The aim of this study is to differentiate expression PD-L1 in lung adenocarcinoma and lung squamous cell carcinoma.